GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Aims: The purpose of this study is to compare a combination of radiation therapy and weekly treatment of the chemotherapy drug cisplatin to the standard treatment for this type of cancer which is radiation therapy alone. This study will also evaluate the side effects of combining radiation therapy and chemotherapy with cisplatin. 
Diagnosis: Recurrent Endometrial Cancer 
Principal Investigator: Jean Hurteau, MD 
IRB Approval Number: EH09-122
Sponsor: Gynecologic Oncology Group (GOG) 
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698 
Open to Enrollment: Yes 

GOG 0274: The OUTBACK Trial: A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial
Aims: The purpose of this study is to compare standard treatment; radiation therapy combined with the chemotherapy drug cisplatin (called chemo-radiation), to standard treatment plus additional investigational chemotherapy with the FDA approved agents, carboplatin and paclitaxel. The study will see if the addition of these chemotherapy agents will reduces the risk of tumor recurrence and improves overall survival. 
Diagnosis: Advanced Cervical Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH12-455
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG 0277: A Phase III Randomized Trial of Gemcitabine (NSC #613327) plus Docetaxel (NSC #628503) followed by Doxorubicin (NSC # 123127) versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Aims: In this study, we are looking to see if giving chemotherapy with gemcitabine plus docetaxel, followed by doxorubicin, to patients whose leiomyosarcoma was found only in the uterus, decreases the chance that the leiomyosarcoma will come back (recur).
Diagnosis: Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH13-299
Sponsor: Gynecologic Oncology Group (GOG)  
Contact: Interested patients should contact study coordinator Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG 0286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measureable Stage II or IVA, Stage IVB, or Recurrent Endometrial Cancer
Aims: The purpose of this study is to find out if the drug combination paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating your type of cancer and to find out what side effects are caused by treatment with these drugs.
Diagnosis: Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH14-321
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study coordinator Elita Fine at 847.570.2698
Open to Enrollment: Yes

× Alternate Text